Search research articles
Contact Us
Filters
Showing results (181-190 of 203) with videos related to
Page
of 21
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 2, 2016
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Celalettin Ustun, Jason Gotlib, Uday Popat, et al.
The Journal of Allergy and Clinical Immunology
|
March 22, 2021
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
Jason Gotlib, Tracy I George, Melody C Carter, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
Peter Valent, Karin Hartmann, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Peter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium
Peter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Polina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Jason Gotlib, Juliana Schwaab, William Shomali, et al.
Journal of the American Academy of Dermatology
|
February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study
Frank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
British Journal of Haematology
|
September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study
Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 203) with videos related to
Sort By:
Page
of 21
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 2, 2016
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Celalettin Ustun, Jason Gotlib, Uday Popat, et al.
The Journal of Allergy and Clinical Immunology
|
March 22, 2021
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
Jason Gotlib, Tracy I George, Melody C Carter, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
Peter Valent, Karin Hartmann, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Peter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium
Peter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Polina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Jason Gotlib, Juliana Schwaab, William Shomali, et al.
Journal of the American Academy of Dermatology
|
February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study
Frank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
British Journal of Haematology
|
September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study
Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
Page
of 21